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The credibility of health economic models for
health policy decision-making: the case of
population screening for abdominal aortic
aneurysm
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Health Economics Research Centre, Department of Public Health, University of Oxford; 1Health Economics Research Group, Brunel
University, Middlesex; 2MRC Biostatistics Unit, Institute of Public Health, University of Cambridge, Cambridge, UK
Objectives: To review health economic models of population screening for abdominal aortic aneurysm
(AAA) among elderly males and assess their credibility for informing decision-making.
Methods: A literature review identi¢ed health economic models of ultrasound screening forAAA. For each
model focussing on population screening in elderlymales,model structure and input parameter valueswere
critically appraised using published good practice guidelines for decision analytic models.
Results: Twelve models published between 1989 and 2003 were identi¢ed. Converting costs to a common
currency and base year, substantial variability in cost-e¡ectiveness results were revealed. Appraisals car-
ried out for the nine models focusing on population screening showed di¡erences in their complexity, with
the simpler models generating results most favourable to screening. Eight of the nine models incorporated
two or more simplifying structural assumptions favouring screening; uncertainty surrounding these
assumptions was not investigated by any model. Quality assessments on a small number of parameters
revealed input values varied between models, methods used to identify and incorporate input data were
often not described, and few sensitivity analyses were reported.
Conclusions: Large variation exists in the cost-e¡ectiveness results generated by AAA screening models.
The substantial number of factors potentially contributing to such disparities means that reconciliation of
model results is impossible. In addition, poor reporting of methods makes it di⁄cult to identify the most
plausible and thus most useful model of those developed.
Introduction
In the UK, decision analytic models are increasingly
used to estimate the costs and outcomes of alternative
health care interventions. Cost-effectiveness data pre-
sented to the National Institute for Health and Clinical
Excellence (NICE), the body responsible for appraising
health technologies on behalf of the UK National
Health Service (NHS), are largely model based.1
The appeal of decision modelling is its versatility. Its
uses include extrapolation beyond trial outcomes,
evidence synthesis, generalization of study results to
alternative settings and identiﬁcation of future research
priorities.2 However, concerns about decision models
(notably a lack of methodological rigour and transpar-
ency) have been raised and policy-makers still regard
decision model ﬁndings with caution.
Population ultrasound screening for abdominal
aortic aneurysm (AAA) in elderly males provides a
good example. The effectiveness and cost-effectiveness
of a national screening programme for AAA has been
debated in many countries over many years.3,4 First
attempts around 1990 to determine the likely cost-
effectiveness of a screening policy involved some simple
modelling studies.5,6 By 2000, the number of models
had increased substantially. A large pragmatic rando-
mized trial of AAA screening in the UK provided the
ﬁrst trial-based estimates of effectiveness and resource-
use in 2002.7 But with follow-up limited to four years,
analysts have continued to develop models to estimate
long-term cost-effectiveness. However, there is little
evidence that these models have assisted decision-
makers in determining whether or not screening for
AAA is cost-effective. As of October 2005, longstanding
decisions to refrain from screening all elderly males,Correspondence to: helen.campbell@dphpc.ox.ac.uk
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which were made in the absence of deﬁnitive cost-
effectiveness evidence, continue to be upheld in the
United States,3 Canada,4 and the UK.
That policy-makers appear unable or unwilling to
make recommendations for (or against) AAA popula-
tion screening on the basis of results generated
predominantly by decision analytic models, raises a
number of important questions. The aim of this paper
was to identify and review published AAA screening
models, with a view of determining their credibility for
informing policy.
AAAs and screening
AAAs are present in 5–7% of men over 65 and account
for approximately 2% of deaths in this group in the
UK. In most cases, the aortic dilation is asymptomatic,
going undetected until rupture. Prognosis following
rupture is bleak as around half of patients will die
before they reach hospital and the remaining half will
face emergency surgery mortality rates ranging from
30% to 70%. Ultrasound is a low-cost, non-invasive,
sensitive and speciﬁc screening test for early detection
of AAA. Following detection, AAAs can be monitored
for growth, and patients referred for elective surgical
repair when the aneurysm exceeds a size beyond which
the probability of rupture is considered high.
Methods
Full details of the terms used and databases included in
the search for health economic models of AAA screen-
ing are available as a web appendix together with other
methodological details. The web appendix may be
viewed free of charge at http://www.ingentaconnect.com/
content/rsm/jhsrp/2007/00000012/00000001/art00005. All
ﬁelds within databases were searched in February 2005
for papers or reports published up to and including
2004, with no language restrictions. Papers reporting
health economic models were reviewed, and costs
expressed as 2003/2004 £ Sterling to facilitate a
comparison of results.
Only models for population screening among
elderly males were critically appraised. The structure
of each model was assessed using guidelines for
good practice in decision analytic modelling in
health technology assessment (Table 1).8 An appraisal
of the data used to inform three key parameters
(a clinical parameter, a cost parameter and an
outcome parameter) common to each model was
also carried out. For each, an assessment was made
of the methods used to (1) identify, (2) incorporate and
(3) handle uncertainty around model input data.9
Where papers had referenced another publication as
the source of input data, this publication was retrieved
and reviewed.
Results
Twelve health economic models of AAA screening were
identiﬁed. Table 2 presents base-case results reported
or derivable for each model. Where studies reported
results for more than one screening strategy, or for
different patient groups, those pertaining to a single
ultrasound screen, and to all elderly males, were
sought. Where estimates of the additional cost per
patient resulting from AAA screening were reported,
values ranged from £65 to £460. Effect differences
ranged from –0.001 to 0.28 among studies reporting
life years and 0.031 to 0.077 among those reporting
quality–adjusted life years (QALYs). Incremental cost
per life year gained ﬁgures ranged from £101,443 to
£35,187, and incremental cost per QALY ﬁgures from
£817 to £7,738.
A detailed assessment of the structure and input
parameter values of nine of the models in Table 2 was
undertaken. The remaining three models were
excluded (grey shading in Table 2), two because their
focus was targeted ultrasound screening for familial
AAA,10,11 and one because analysts failed to report any
of the statistics in Table 2.12
Table 1 Issues for consideration with regard to model structure8
No. Heading Description
1 The decision problem/
objective
 The problem needing to be addressed, i.e. the disease/condition involved, the patient group, and the
intervention to be evaluated
 The objective of the evaluation/model
 The primary decision-maker.
2 The study perspective/scope  The perspective adopted for the analysis. Model inputs should be consistent with this perspective
3 Rationale for model structure  The model structure should represent the underlying disease process, and the impact of the
intervention
 Sources of data used to develop the model structure should be reported
4 Structural assumptions  Assumptions made while structuring the model – these should be justiﬁed and be reasonable
 Uncertainty associated with structural assumptions should be examined using sensitivity analysis
5 Strategies/comparators  Alternative strategies being evaluated
6 Model type  The model type used, e.g. decision tree, Markov model. This will be determined by the decision
problem
7 Time horizon  The length of follow-up in the evaluation – this should extend far enough into the future to capture all
costs and consequences associated with the interventions being compared
8 Disease states/pathways  Disease states or pathways through the model – these should reﬂect important events in the
underlying process of the disease/condition
9 Cycle length  In discrete time models – the duration of time before the model cycles. This period should correspond
to the minimum period over which a change in disease status could be expected to occur
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Model structures
All papers had a stated objective to estimate the cost-
effectiveness of a population ultrasound screening
programme for AAA compared with no screening.
Only two papers provided details of funding sources,
and none indicated whether the modelling had been
commissioned directly by a health care provider or
conducted independently. The study viewpoint was
explicitly stated in only one paper,13 although all
models used inputs consistent with a health care
provider’s perspective.
Consideration of the strategies being modelled
showed the age at which men were initially screened
varied from 60 to 79. In six papers,13–18 a policy of a
single (or prevalence) population screen was modelled
and in three papers, policies involving multiple
population screens were presented.5,6,19 If estimates
of the annual incidence of new AAA of 0.1% per annum
are to be believed,15,19 then the prevalence of AAA at
subsequent screens will be small. In terms of cost-
effectiveness, and when comparing against a policy of
no screening, one might expect a policy involving
re-screens of the same cohort to appear less favourable
than a single screen strategy. Table 2, however, shows
that incremental cost-effectiveness ratios (ICERs) from
two of the three studies were among the three most
favourable reported.5,6
Cross-referencing model type with the results in
Table 2 revealed that the three studies reporting the
lowest ICERs5,6,18 were also the three not employing a
decision analytic framework to model explicitly costs
and effects. Although a number of terms (including
mathematical model, computer spreadsheet model and
Markov model) were used to describe the remaining six
models, each used Markov modelling. The underlying
disease process appears to provide the rationale for the
structure of these six models, with the health states
included in each model reﬂecting important clinical
stages in the disease process (e.g. no AAA, small,
medium and large AAA). Each model appears to cycle
on a yearly basis; however, in only one paper,17 this is
stated explicitly.
In terms of the time horizon modelled, ﬁve studies
conducted a lifetime analysis,5,14,16–18 three used 20
years,6,15,19 and one used 15 years.13 Given the starting
age of the patient cohort, 15 or 20 years might be
considered broadly equivalent to a lifetime analysis and
therefore time horizon is unlikely to be a signiﬁcant
factor contributing to disparate results.
Eight of the nine models incorporated two or more
simplifying structural assumptions favouring screen-
ing, and so cost-effectiveness results could be overly
optimistic. Four of the nine models appear to assume
that without screening, opportunistic detection of AAA
and resultant elective repairs would not occur.5,6,13,14
Although data on AAA diagnosis in the absence of
screening are scarce, patients still undergo elective AAA
repair in the absence of formal screening programmes.
Omitting some level of natural case ﬁnding will
over-estimate to some degree lives saved and life years
gained by implementation of such screening. In a one-
way sensitivity analysis conducted by one of the ﬁve
models, which allowed for opportunistic detection,
reduction of the base-case estimate from 6.6% per year
to zero had only a small effect on the ICER.16
Four of the nine models seem to be structured for
100% attendance at screening.6,15,16,19 Pilot studies of
AAA screening have suggested attendance of around
80%. An assumption that all invited patients attend will
tend to make screening appear more favourable than it
would be in routine practice. Ideally models should
reﬂect the positive association between attendance rates
and invitation costs (i.e. only re-invitation and persis-
tent follow-up of non-responders can improve turn-
out). Table 2 shows that despite assuming 100% take-up
of screening, three of these four studies still generated
the highest ICERs. One-way sensitivity analysis by one
of the models structured for non-attendance suggested
only small reductions in cost-effectiveness as atten-
dance declines.17
All nine analyses assume ultrasound sensitivity and
speciﬁcity to be 100%. While the test is unlikely to be
perfectly accurate, evidence suggests its sensitivity and
speciﬁcity are close to 100%.20 Given the uniformity of
this assumption, it cannot be a factor contributing to
the between-model differences in cost-effectiveness
results.
Assumptions about the impact of screening upon
AAA rupture vary between studies. Table 3 shows that
one study assumes that screening will completely
eliminate rupture and emergency surgery.19 In addi-
tion to 100% attendance at screening and 100%
sensitivity and speciﬁcity of ultrasound, two further
assumptions would need to hold in order for this to be
true: ﬁrstly no ruptures in patients with screen-
detected AAA below the threshold for surgery, and
secondly all patients with screen-detected AAA exceed-
ing this threshold undergo elective repair without
delay. As the threshold for surgery used in this study
is small (40mm) and rupture of an AAA of this size is
unlikely, the ﬁrst of these two assumptions could be
considered valid. That all patients indicated for elective
repair will undergo the procedure is, however,
improbable, although Table 3 shows a further two
studies also making this assumption.6,16 Only ﬁve of the
papers acknowledged that not all patients exceeding
the threshold for elective repair would undergo
surgery, either because they refused or were contra-
indicated for the procedure, or because they failed to
attend the initial screen and their AAA remained
undetected.5,13–15,17
Table 3 suggests that the size of aneurysm threshold
beyond which elective repair is indicated has increased
over time. The four most recent studies, which use
larger diameter thresholds, all acknowledge a small risk
of rupture below this size. It is difﬁcult to determine the
impact of these assumptions upon cost-effectiveness
results. From Table 3, it could be inferred that two
models13,17 simulate the most likely impact of screening
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upon AAA rupture, since only they permit rupture
both below and above the threshold. Table 2 shows,
however, that the results from these models were
among the most favourable towards screening.
Elective AAA repair mortality rate
Base-case estimates of this parameter varied between
studies. (Table 2 on web) The two studies using the
lowest rates5,18 produced the lowest cost-effectiveness
ratios. Higher mortality rates, however, were not always
associated with less favourable results. Only two studies
provided details of bibliographic searches to identify
papers to inform this parameter value.15,17 Three
studies provided no reference at all for the base-case
estimate used.5,16,18 Of the six studies that did cite
sources, three referenced just one publication13–15
(although one of these contained results of a Medline
review), and one each referenced two papers,17 three
papers,6 and four papers.19 Of those studies citing
more than one source, none provided information on
how estimates from these studies were synthesized to
generate the base-case value incorporated within the
model.
Four of the nine studies reported sensitivity analyses
for this parameter. Of the three performing one-way
analyses, two demonstrated that small changes in
mortality following elective AAA repair would have a
large impact upon cost-effectiveness.14,19 The report-
ing of sensitivity analysis results from the third study,
however, did not use the ICER.13 The remaining paper
carrying out sensitivity analysis for this parameter did
so as part of a multivariate analysis.15
Cost of emergency AAA repair
The assumed cost of emergency AAA repair varied
substantially across the nine models. (Table 3 on web)
Around half of the analysts used a base-case cost that
they had estimated themselves16–19 and in one paper
both a locally calculated cost and a published cost were
used.13 For just two of these studies, detail was available
(in a further published paper) on resource-use
included in the estimate, and costing methods
used.13,16 Of the remaining four studies, cost estimates
used by three appear to be based on expert clinical
opinion5,6 or personal communication14 and one study
referenced a single paper reporting a costing exer-
cise.15 Details on the costing methods employed and
resource-use included in this estimate were not,
however, reported.
Four of the nine studies reported sensitivity analyses
for the cost estimate of emergency AAA repair. Two of
these studies undertook one-way sensitivity ana-
lyses;13,19 however, it was possible to determine the
impact of variation in the cost estimate on the ICER for
only Bengtsson et al.19 who found that doubling the
emergency surgery cost reduced their base-case incre-
mental cost per life year by 30%. Of the remaining two
studies, one reduced the costs of elective and emer-
gency repair to the same value simultaneously,14 while
the impact of varying the cost of emergency AAA repair
in the remaining paper was again assessed at the same
time as other parameter values were varied.15
Utility levels assigned to life years modelled
Of the four studies using the QALY as their outcome
measure, two assigned a utility level of one to all
life years modelled.13,18 (Table 4 on web) Neither of
these studies provide justiﬁcation for such an assump-
tion, nor do they examine uncertainty surrounding this
value. Perfect health was also generally assumed for
patients in another model; however, utility for AAA
repair survivors in this model was reduced slightly in
the three-month period following surgery to reﬂect
Table 3 Threshold sizes for elective surgery and structural assumptions relating to rupture and emergency surgery in the screening arms of
models, ordered by date of publication
Study <Threshold >Threshold
Model structured to allow
rupture and emergency
surgery in screening arm
Threshold for surgery Model structured to allow
rupture and emergency
surgery in screening arm
Bengtsson et al. (1989)19 No 40mm No
Russell (1990)5 NA 40mm Yes
Collin (1990)18 NAw 40mmz NAw
Mason et al. (1993)14 No 50mm Yes
Frame et al. (1993)15 No 40mm Yes
Law et al. (1994)6 Yesy 60mm No
St Leger et al. (1996)13 Yes 60mm Yes
Lee et al. (2002)16 Yes 50mm No
Boll et al. (2003)17 Yes 50mm Yes
Text accompanying model acknowledges that not all patients identiﬁed as surgery candidates will undergo elective AAA repair. Whether
ruptures occurring in this group are fed through into the modelling is unclear
wIt is acknowledged that rupture and emergency surgery will still occur with screening, but the AAA size at which rupture is permitted is not
speciﬁed
z40mm mentioned in text as a likely threshold for surgery, inclusion in the model is unclear
yText accompanying model acknowledges that rupture will still occur below the threshold for surgery. Whether this is fed through into the
modelling is unclear
NA – information not available
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procedure-related morbidity.5 Disutility associated with
AAA repair was also incorporated within the model by
Lee et al.,16 as were utility levels associated with possible
long-term complications. Again no sources were pro-
vided for utility values used and no sensitivity analyses
exploring the impact of alternative values were
conducted.
Discussion
There is a lack of agreement between models, which
raises questions about the overall quality of the
modelling employed. Any decision-maker attempting
to review these models would be confronted with poor
reporting of results. In only four papers, it was possible
to derive estimates of the mean per patient costs and
outcomes with and without screening. No improve-
ment in the standard of reporting over time was
apparent.
Although 10 models generated ICERs well below
£20,000 (which is likely to be considered cost-effective
in most jurisdictions),21 considerable uncertainty sur-
rounds the additional costs that would need to be
incurred to generate additional health beneﬁt. Given
the substantial number of factors with the potential to
inﬂuence model results, attributing these differences to
speciﬁc modelling techniques, structural assumptions
or parameter values is simply not possible. We can
only speculate about the possible relative impact of
different study components. Model type, for example,
could be a contributing factor – none of the three
studies generating results most favourable to screening
constructed a model framework to model costs and
effects explicitly.
Examination of structural or simplifying assumptions
revealed eight of the nine population screening
models to have incorporated at least two assumptions,
which would artiﬁcially favour a screening
programme. Although consideration of each assump-
tion in isolation suggested the likely impact in terms
of overestimating cost-effectiveness might be small,
the collective impact of these assumptions on the
results of each model is uncertain, and effectively
impossible for a decision-maker to determine. It
might be concluded that Law et al.6 incorporated
the most number of assumptions in favour of
screening and that this resulted in a model generating
one of the lowest ICER values. In contrast, the model
by Boll et al.17 incorporated the least number of
structural assumptions in favour of screening. How-
ever, it too generated results highly favourable towards
screening.
One other possible source contributing to the
divergent results are the data used to populate these
models. Having to compare and ascertain the quality of
all input parameter values across all nine models
highlights the enormity of the task facing the deci-
sion-maker. Assessing data quality for just three model
parameters revealed a wide range of input values for
each. The relation with reported results was not always
intuitive, given the base-case parameter values
reported.
Disparate results among models evaluating the same
interventions have been observed elsewhere.22–24
When convergent validity between models is low, and
reconciliation of disparate results not achievable, the
decision-maker will need to determine whether results
from any of the models are robust enough to inform
policy. For AAA screening models, determining the
reliability of model input parameters and consequently
of cost-effectiveness results is simply not possible. Good
practice guidelines for decision analytic models suggest
that the analyst should document all the information
sources that have been searched.9 Such details are
rarely reported. Without this information, the decision-
maker cannot judge whether parameter values are
appropriate. A lack of methodological rigour in
reporting search strategies for identifying data to
populate decision models has also recently been
observed by Cooper et al.2 in decision models devel-
oped for UK Health Technology Assessments. They
found that for model parameters (with the exception of
clinical effectiveness data), methods used to identify
sources of evidence were rarely reported and appeared
to be ad hoc.
In the absence of suitably robust decision models,
interaction between researchers and decision-makers
could provide an opportunity to improve both the
transparency and usefulness of published analyses. In
the UK, for example, NICE commissions work and
interacts with analysts, which facilitates the modelling
of alternative scenarios.
Despite not being able to determine whether models
were commissioned directly by decision-makers or
conducted by independent analysts, we assumed that
models were devised so as to meet the requirements of
a decision-maker and would have been known about
and considered at the time of policy review. Input
parameters were certainly consistent with a health
service viewpoint, suggesting the ﬁrst of these assump-
tions to be plausible. Furthermore, a recently published
synthesis showed that decision-makers systematically
search for and identify the majority of published
models.3
Conclusion
There are a number of reasons why cost-effectiveness
models may not have provided an adequate basis to
encourage policy-makers to adopt population screen-
ing for AAA. First, convergent validity between models
is low. Second, it is extremely difﬁcult based upon the
data reported in published studies to attribute differ-
ences in results to one or more particular sources.
Third, poor reporting of methodology makes it
difﬁcult to ascertain whether the modelling carried
out is of a sufﬁciently high standard to inform policy-
making. There need to be major improvements in the
construction and reporting of health economic decision
For Evaluation Only.
Copyright (c) by Foxit Software Company, 2004 - 2007
Edited by Foxit PDF Editor
models if they are to contribute to health policy
decisions.
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Web appendix
Methods
Literature review methods
To identify papers reporting the results of models
constructed to estimate the cost-effectiveness of AAA
screening, the following search terms were used:
‘Abdominal Aortic Aneurysm or AAA or Aneurysm’’
and ‘Screen’ and ‘Survival or Life Years or Quality
Adjusted Life Years or Life Expectancy or QALYs’ and
‘Model’. The following bibliographic databases were
searched in February 2005 –Medline, EMBASE, EconLit,
CINAHL, CAB Health, British Nursing Index (BNI),
Biological Abstracts, MathSci, NHS Economic Evaluation
Database (NHS EED), the Database of Abstracts of Reviews
of Effects (DARE), the Ofﬁce of Health Economics Health
Economic Evaluations Database (OHE HEED), and the
Health Technology Assessment (HTA) Report series. All ﬁelds
within databases were searched for papers or reports
published up to and including 2004. No restrictions
were placed upon publication language. Figure 1 shows
the ﬂow of publications.
Papers identiﬁed as reporting health economic
models were reviewed and results documented. To
facilitate a comparison of results, all costs were inﬂated
to 2003/2004 UK £ Sterling. For non-UK studies
identiﬁed, costs were inﬂated to 2003/04 prices using
country-speciﬁc inﬂation indices1 before being
converted to UK £ Sterling using published Purchasing
Power Parities (PPPs).2 Ideally, PPPs speciﬁc to AAA
screening and treatment would have been used – such
technology-speciﬁc indices are known to accurately
account for issues of resource-use mix and price
variation,3 but these were not available. However, given
that only western countries feature in the review, it is
likely that the potential for resource-use mix to differ
substantially in the provision of AAA screening and
treatment is small.
References
1 Organisation for Economic Co-operation and Development.
OECD Health Data 2003. Paris, France: Organisation for
Economic Co-operation and Development, 2003
2 Organisation for Economic Co-operation and Development.
OECD Health Data 2004 1st edn. Comparative Analysis of 30
Countries Paris, France: Organisation for Economic Co-
operation and Development, 2004
3 Wordsworth S, Ludbrook A. Comparing costing results in
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speciﬁc purchasing power parities. Health Econ 2005;14:
93–9
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aBNI British Nursing Index 
bUS United States 
cRCTs Randomized Controlled Trial
93 hits from
literature search
Source of publications n=93 
• Medline n=25 
• Embase n=17 
• EconLit/CINAHL/CAB Health n=14 
• BNIa/Biological Abstracts/MathSci n=9 
• NHS EED, DARE, HTA n=12 
• OHE HEED n=16 
48 abstracts reviewed 
Publications removed:
41 duplications
4 abstracts
Publications removed: 
37 inappropriate
11 papers obtained in 
full
Publications removed:
2 inappropriate
Publications added:
3 already known to the
authors
12 papers presenting
AAA screening models
(Summarized in Table 2)
Reasons for exclusion n=37 
Publication related to:
• Screening for cerebral/intracranial aneurysm n=13
• Screening for other conditions e.g. metabolic syndrome, 
carotid artery disease n=6 
• USb Agency for Health Care Policy and Research’s 
Clinical Guidelines for various conditions n=4 
• Predicting clinical events for AAA patients following 
surgery n=3 
• The reporting of data/results from RCTsc of screening for 
AAA n=3 
• The cost-effectiveness of early surgery versus watchful 
waiting for small AAA n=2 
• Results of an AAA population screening programme n=1 
• Functional status and well being of AAA patients n=1 
• Chapter in report of the USb Preventive Services Task 
Force on Screening for AAA n=1 
• RCTsc for the management of other conditions n=2 
• Role of genes in the Staphylococcus aureus n=1
Reasons for exclusion n=2 
• Article presenting evidence against screening for AAA n=1 
• Study modelling the cost-effectiveness of screening and 
cardiac revascularization prior to vascular surgery for 
known AAA patients n=1
9 papers critically 
appraised
Publications removed: 
3 inappropriate 
Reasons for exclusion n=3 
• Models of screening for familial AAA n=2 
• Study failing to report useful summary measures and 
undertake an incremental analysis n=1
Figure 1 Flow of publications identiﬁed
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Appendix Table 1 Structural elements of the nine cost-effectiveness models, ordered by date of publication
Model
Reference no. 19 5 18 14 15
Bengtsson H, et al. Russell J Collin J Mason J, et al. Frame, et al.
Strategies A US screen for men
aged 60 with re-
screen at 67 and 74
for those with
negative results is
compared with no
screen
A US screen for males
at age 60, then
again at 65 and 70
is compared with
no screen
A single US screen for
men aged 65 is
compared to no
screen
A single US screen for
men aged 70 is
compared to no
screen
A single US screen for
men between 60
and 79 is compared
with no screen
where emergency
and elective AAA
treatment is
permitted
Model type and
structure
Described as a
mathematical
model. Appears to
be based on
principles of
Markov modelling
and is structured to
reﬂect the
underlying disease
process and impact
of screening
No model framework
has been
constructed
No model framework
has been
constructed
Model type not
documented but
appears to be
based on the
principles of
Markov modelling
and is structured
to reﬂect the
underlying disease
process and
impact of
screening
Described as a
computer
spreadsheet
model. Appears to
be based on the
principles of
Markov modelling
and is structured to
reﬂect the
underlying disease
process and impact
of screening
Model appears to be
used only for
screening arm
Only patients for
whom screening
alters
management are
included in the
model
Model is used for both
screening and no
screening arms
Disease states
and cycle
length
Health states include
no AAA, AAA
29–39mm, AAA
>39mm
NA – no model
constructed
NA – no model
constructed
Health states include
AAA 35–50mm
undetected,
AAAX50mm
undetected, AAA
35–50mm
detected,
AAAX50mm
detected
Health states include
no AAA, AAA o
4 cm undetected,
AAA o 4 cm
detected, AAA >
4cm undetected,
AAA>4cm
detected when
o4 cm and not
examined since,
AAA > 4cm
detected, death
Cycle length appears
to be one year
Cycle length appears
to be one year
Cycle length appears
to be one year
Time horizon 20 years Lifetime Lifetime Lifetime 20 years
Structural
assumptions
No mention of
opportunistic
detection and
elective AAA repair
in the absence of
screening
Opportunistic
detection and
elective AAA
repair in the
absence of
screening is
assumed zero
100% attendance at
screening is
assumed
100% attendance at
screening is
assumed
Ultrasound is assumed
100% sensitive and
speciﬁc
Ultrasound is assumed
100% sensitive and
speciﬁc
Ultrasound appears to
have been
assumed 100%
sensitive and
speciﬁc
Ultrasound is
assumed 100%
sensitive and
speciﬁc
Ultrasound is assumed
100% sensitive and
speciﬁc
Model
Reference no 6 13 16 17
Law et al. St Leger et al. Lee et al. Boll et al.
Strategies Two US screens for
men, one at age 60
and one at age 70,
is compared with
no screen
A single US screen for
men aged between
68 and 72 is
compared with no
screen
A single US screen for
men aged 70 is
compared with no
screen
A single US screen for men aged 60–65 is
compared with no screen
Model type and
structure
No model framework
has been
constructed
Described as a
computer
spreadsheet
model. Appears to
be based on the
principles of
Markov modelling
A Markov model is
used and is
structured to reﬂect
the underlying
disease process
and the impact of
screening
A Markov model is used and is structured to
reﬂect the underlying disease process and
the impact of screening
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Appendix Table 1 (Continued)
Model
and is structured to
reﬂect the
underlying disease
process and impact
of screening
Model is used for both
screening and no
screening arms
Model is used for both
screening and no
screening arms
Model is used for both screening and no
screening arms
Disease states
and cycle
length
NA – no model
constructed
Health states include
No AAA, nine
‘categories’ for
different AAA sizes
(all detected and
undetected), death,
and survivor
Health states include
AAA o 3 cm, AAA
3–4 cm, AAA
4–5 cm, AAA
>5cm (all
detected and
undetected),
surgery survivor,
and death
Health states include No AAA, unknown small
AAA, follow-up small AAA, unknown large
AAA repaired AAA, rejected large AAA, and
death
Cycle length is one
year
Cycle length appears
to be one year
Cycle length is one year
Time horizon 20 years Five-year model, with
10 years of life
expectancy
assigned to lives
saved by screening
Lifetime Lifetime
Structural
assumptions
No mention of
opportunistic
detection and
elective AAA repair
in the absence of
screening
Opportunistic detection
and elective AAA
repair in the
absence of
screening is
assumed zero
100% attendance at
screening is
assumed
100% attendance at
screening is
assumed
Ultrasound appears to
have been
assumed 100%
sensitive and
speciﬁc
Ultrasound is assumed
100% sensitive and
speciﬁc
Ultrasound appears to
have been
assumed 100%
sensitive and
speciﬁc
Ultrasound appears to have been assumed
100% sensitive and speciﬁc
For structural assumptions relating to rupture and emergency repair with screening, see Table 3 in the journal
Appendix Table 2 Assessment of methods used to identify, incorporate, and examine uncertainty around mortality rate for elective AAA repair
Study Baseline estimate of
elective AAA repair
mortality rate
Detail provided of
bibliographic databases
searched to inform
parameter value
Data source(s) and
methods used to generate
baseline parameter value
Sensitivity analysis
Bengtsson H,
et al.19
6% No –data described as coming
from ‘own experience’ and
published literature
Four studies (1 Australian, 1
US, 1 Swedish, 1
Norweigan), each reporting
operative mortality among
a series of patients
undergoing elective AAA
repair. Rates reported
range from 3.7% to 12%
One-way sensitivity
analysis using rates of
3% and 12%
Method used to synthesize
data not described
Russell J5 2% No No source referenced No sensitivity analysis
undertaken
Collin J18 3% mentioned in text.
Inclusion in model is
unclear
None searched – model input
data reported to be based
upon local experience
No description provided of how
ﬁgure was generated
No sensitivity analysis
undertaken
Mason J, et al.14 5% No A letter published in a UK
journal where rates quoted
are from 1.4% to 10%
One-way sensitivity
analysis using rates of
4% and 3%
Method used to synthesize
data not described
Frame P, et al.15 5% Systematic review augmented
by an additional search of
Medline and manual
searching of paper
bibliographies
Figure is reported in a paper
publishing results of the
Medline searches. Sixteen
studies appear to have
informed this value
Two multivariate sensitivity
analyses setting all
model parameters
simultaneously to
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Appendix Table 2 (Continued)
Study Baseline estimate of
elective AAA repair
mortality rate
Detail provided of
bibliographic databases
searched to inform
parameter value
Data source(s) and
methods used to generate
baseline parameter value
Sensitivity analysis
values most and least
favourable to screening
Method used to synthesize
data not described
Law M, et al.6 5% No Three studies (1 UK, 2 US),
each reporting operative
mortality among a series of
patients undergoing
elective AAA repair. Rates
reported range from 1.4%
to 4.9%
No sensitivity analysis
undertaken
Methods used to synthesize
data are not described
St Leger A, et al.13 5% No –model input data reported
to be gleaned from the
literature
One UK study reporting
operative mortality among
a series of patients
undergoing elective AAA
repair
One-way sensitivity
analysis using rates of
0%, 2%, 4%, 5%, 6%,
8% and 10%. Method of
presenting results,
however, does not
conform with
convention
Lee T et al.16 4% No – data were informed by a
retrospective literature
review
No sources referenced –
details available from
authors on request
One-way sensitivity
analysis undertaken but
uncertainty around
elective AAA repair
mortality rate was not
explored
Figure used is reported to be a
weighted average
Boll A et al.17 6.8% Published data from a Medline
search and manual
searching of bibliographies
from relevant papers
Two papers, of which one is a
‘seminar’ published in a UK
journal. Rates reported are
from 4% to 8%. The source
of these estimates is the
second paper which
reports operative mortality
among all patients with
non-ruptured AAA
undergoing elective repair
in the Netherlands in 1990
One-way sensitivity
analysis undertaken but
uncertainty around
elective AAA repair
mortality rate was not
explored
Results expressed as an ‘absolute’ cost per QALY calculated by dividing total costs in the screening arm of the model by the additional life years
gained from screening
Appendix Table 3 Assessment of methods used to identify, incorporate and examine uncertainty around the cost of emergency AAA repair
Study Baseline estimate of
cost of emergency
AAA repair
(£ UK 03/04)
Detail provided of
bibliographic databases
searched to inform
parameter value
Data source(s) and
methods used to generate
baseline parameter value
Sensitivity analysis
Bengtsson H et al.19 £16,040 None searched – costs were
calculated locally
Estimate based on data from 10
patients undergoing
emergency repair in a
Swedish General Hospital.
No description is given of
the costing methods used or
of what resource-use is
included in the estimate
One-way sensitivity
analysis doubling the
baseline cost of
emergency repair
Russell J5 Not stated. Assumption
appears to be that
elective and
emergency repair
cost the same at
£5,558
No If the aforementioned
assumption is correct, the
cost-estimate is based on a
value reported in a letter
published in a UK journal.
The value per se appears to
be based on expert clinical
opinion
No sensitivity analysis
undertaken
Collin J18 £11,115 None searched – model input
data reported to be based
on local experience
No description provided of
costing methods used or
resource use included
No sensitivity analysis
undertaken
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Appendix Table 3 (Continued)
Study Baseline estimate of
cost of emergency
AAA repair
(£ UK 03/04)
Detail provided of
bibliographic databases
searched to inform
parameter value
Data source(s) and
methods used to generate
baseline parameter value
Sensitivity analysis
Mason J et al.14 £5,212 No Reported to be a personal
communication from a UK
hospital
Two-way sensitivity
analysis using an extra-
contractual referral cost
for a general surgical
procedure for both
emergency and elective
repairs
Frame P et al.15 £44,037 Systematic review augmented
by an additional search of
Medline and manual
searching of paper
bibliographies
A published US study which
costed surgery for 12
patients undergoing
emergency repair. No
description is given of the
costing methods used and it
is unclear what resource-
use is included in the
estimate
Two multivariate sensitivity
analyses setting all
model parameters
simultaneously to
values most and least
favourable to screening
Law M et al.6 £11,115 No The modelling study by
Collin J18
No sensitivity analysis
undertaken
St Leger A et al.13 One published study, which
applied costs from a UK
hospital to estimates of
average resource use
consumed during an
emergency AAA. Resource-
use items are listed and a
micro-costing approaches
used
Baseline results generated
using both published
and calculated cost
estimates
£5,668 (locally
calculated cost)
No – cost was obtained from
the literature, and in
addition a ﬁgure calculated
locally
Second estimate was based on
data from 8 patients
undergoing emergency
repair in a UK hospital. No
description is given of the
costing methods used or
what resource-use is
included in the estimate
One-way sensitivity
analysis doubling the
baseline cost of
emergency repair.
Method of presenting
results, however, does
not conform with
convention
Lee T et al.16 £19,553 No – cost was calculated
locally for a previous study
One published study in which
unit costs from a US
hospital are applied to
literature based estimates of
average resource-use
consumed during an AAA
emergency repair
One-way sensitivity
analysis undertaken but
uncertainty around the
cost of emergency AAA
repair was not explored
Resource-use items are listed
and a micro-costing
approach was adopted
Boll A et al.17 £10,894 No – costs reported to be
based on a screening
feasibility study
No description provided of
costing methods used or
resource-use included
One-way sensitivity
analysis undertaken but
uncertainty around the
cost of emergency AAA
repair was not explored
Results expressed as an ‘absolute’ cost per QALY calculated by dividing total costs in the screening arm of the model by the additional life years
gained from screening
Appendix Table 4 Assessment of methods used to identify, incorporate and examine uncertainty around utility levels assigned to life years
modelled
Study Utility level assigned to
life years modelled
Detail provided of
bibliographic databases
searched to inform
parameter value(s)
Data source(s) and
methods used to generate
baseline parameter value (s)
Sensitivity analysis
Russell J5 Three months of disability
(utility score=0.9) for
survivors of AAA repair
No A UK publication provided the
utility reduction estimate
applied following AAA
repair
No sensitivity analysis
undertaken
All remaining life-years
modelled are assigned a
utility level of 1
A report on breast cancer
screening was used to
justify the assumption that
1 life year=1 QALY
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Appendix Table 4 (Continued)
Study Utility level assigned to
life years modelled
Detail provided of
bibliographic databases
searched to inform
parameter value(s)
Data source(s) and
methods used to generate
baseline parameter value (s)
Sensitivity analysis
Collin J18 All life years modelled are
assigned a utility level of 1
No No sources referenced No sensitivity analysis
undertaken
St Leger A,
et al.13
All life years modelled are
assigned a utility level of 1
No No sources referenced One-way sensitivity
analysis undertaken,
but uncertainty around
utility levels was not
explored
Lee T, et al.16 Post elective AAA repair 47
days of reduced utility
No – reported only to have
been derived from the
literature
No sources referenced -
details available from
authors on request
One-way sensitivity
analysis undertaken,
but uncertainty around
utility levels was not
reported
Post emergency AAA repair 52
days of reduced utility
For survivors of AAA repair,
utility is dependent on
whether any long-term
complications occur. Utility
levels are as follows:
No complications 1
Dialysis – dependent renal
failure
0.68
Stroke 0.40
Myocardial infarction 0.88
Major amputation 0.70
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